TRCT
CYCN

Tower Research Capital (TRC)’s Cyclerion Therapeutics CYCN Stock Holding History

Tower Research Capital (TRC)’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27K Buy
+1,849
New +$6K ﹤0.01% 4226
2026
Q1 		– Sell
-3,154
Closed -$4.01K – 5189
2025
Q4 		$4.01K Buy
3,154
+826
+35% +$1.48K ﹤0.01% 4273
2025
Q3 		$5.35K Sell
2,328
-435
-16% -$1.18K ﹤0.01% 4241
2025
Q2 		$8.04K Buy
2,763
+1,709
+162% +$5.1K ﹤0.01% 4026
2025
Q1 		$2.63K Sell
1,054
-1,387
-57% -$4.13K ﹤0.01% 4521
2024
Q4 		$7.86K Buy
2,441
+1,363
+126% +$3.79K ﹤0.01% 4036
2024
Q3 		$2.79K Sell
1,078
-386
-26% -$1.14K ﹤0.01% 4936
2024
Q2 		$3.37K Buy
1,464
+1,431
+4,336% +$4.07K ﹤0.01% 4897
2024
Q1 		$106 Buy
+33
New +$105 ﹤0.01% 5651
2023
Q2 		– Sell
-664
Closed -$6K – 6087
2023
Q1 		$6K Sell
664
-164
-20% -$2.07K ﹤0.01% 4833
2022
Q4 		$11K Buy
828
+376
+83% +$4.45K ﹤0.01% 3802
2022
Q3 		$8K Sell
452
-226
-33% -$3.88K ﹤0.01% 4770
2022
Q2 		$8K Sell
678
-195
-22% -$2.79K ﹤0.01% 4665
2022
Q1 		$19K Sell
873
-264
-23% -$6.36K ﹤0.01% 3571
2021
Q4 		$39K Sell
1,137
-300
-21% -$14.2K ﹤0.01% 2967
2021
Q3 		$88K Buy
+1,437
New +$94K ﹤0.01% 2505
2021
Q2 		– Sell
-335
Closed -$19K – 5524
2021
Q1 		$19K Buy
335
+64
+24% +$4.81K ﹤0.01% 3911
2020
Q4 		$17K Sell
271
-949
-78% -$64.7K ﹤0.01% 3958
2020
Q3 		$148K Buy
1,220
+961
+371% +$110K ﹤0.01% 2829
2020
Q2 		$31K Buy
259
+113
+77% +$9.45K ﹤0.01% 3414
2020
Q1 		$8K Buy
+146
New +$10.4K ﹤0.01% 2111
2019
Q4 		– Sell
-189
Closed -$46K – 3676
2019
Q3 		$46K Buy
189
+68
+56% +$14.7K ﹤0.01% 1850
2019
Q2 		$28K Buy
+121
New +$34.2K ﹤0.01% 1940

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Tower Research Capital (TRC)'s CYCN Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Cyclerion Therapeutics (CYCN) in Q2 2026: 1,849 shares worth $6.27K. The stake represents ﹤0.01% of the portfolio and ranks #4226 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CYCN as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in CYCN in Q2 2019 and has held it in 23 quarters since. The position peaked at $148K in Q3 2020. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Tower Research Capital (TRC) held 1,849 shares of Cyclerion Therapeutics worth $6.27K as of Q2 2026.
  • Cyclerion Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4226 holding.
  • Tower Research Capital (TRC) first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Cyclerion Therapeutics position peaked at $148K in Q3 2020.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.